首页|神经阻滞治疗带状疱疹后神经痛的疗效及对血清白介素-6的影响

神经阻滞治疗带状疱疹后神经痛的疗效及对血清白介素-6的影响

扫码查看
目的 观察神经阻滞治疗带状疱疹后神经痛(PHN)的临床疗效及对血清白介素-6(IL-6)水平的影响.方法 选择2021年10月至2023年5月带状疱疹后神经痛患者60例,随机分为对照组和观察组,每组30例.对照组予以常规治疗口服普瑞巴林、甲钴胺,观察组在对照组治疗的基础上采用超声引导下神经阻滞治疗.观察并记录患者治疗前,治疗后1天、1周、1个月和3个月的疼痛视觉模拟评分法(VAS)评分及血清IL-6水平,并比较两组患者疗效及血清IL-6水平.结果 治疗前对照组和观察组VAS评分分别为(7.00±0.74)(6.73±0.69),IL-6为(93.53±9.15)(92.10± 10.26)ng/L(t分别为1.439、0.570,P均>0.05).治疗后1天对照组和观察组VAS评分分别为(5.23±0.86)(3.97±0.85),IL-6为(83.31±8.54)(72.74±7.64)ng/L(t分别为5.742、5.056,P均<0.05).治疗后1周对照组和观察组VAS评分分别为(4.27±0.69)(3.23±0.77),IL-6 为(75.30±7.89)(64.06±6.02)ng/L(i 分别为 5.454、6.204,P均<0.05).治疗后 1 个月对照组和观察组 VAS 评分分别为(3.57±0.57)(2.80±0.93),IL-6 为(64.05±5.74)(55.86±3.99)ng/L(t 分别为 3.869、6.420,P均<0.05).治疗后3个月对照组和观察组VAS评分分别为(3.07±0.45)(1.87±0.51),IL-6为(55.48±3.39)(48.10±6.10)ng/L(t分别为9.693、5.787,P均<0.05).结论 神经阻滞治疗可明显减轻带状疱疹后神经痛的症状,降低患者血清IL-6水平.
Efficacy of nerve block therapy for postherpetic neuralgia and its effect on serum interleukin-6 levels
Objective To observe efficacy of nerve block therapy in the treatment of postherpetic neuralgia and its effect on the lev-els of serum interleukin-6(IL-6).Methods A total of 60 patients with postherpetic neuralgia treated in the pain clinic of the Sec-ond Xiangya Hospital,Central South University from Oct 2021 to May 2023 were included.They were randomly divided into an observation group and a control group according to different treatment methods with 30 cases in each group.The control group was conventionally treated with pregabalin and mecobalamin.The observation group was treated with pregabalin,mecobalamin and nerve block under ultrasound guidance.The visual analogue scale(VAS)scores and the levels of serum IL-6 before treatment,one day,one week,one month and three months after treatment were observed and recorded;the therapy efficacy and serum IL-6 lev-els were compared between the two groups.Results Before treatment,the VAS scores in the control group and observation group were(7.00±0.74)and(6.73±0.69)(t=1.439,P>0.05),respectively,and the serum IL-6 levels in control group and observation group were(93.53±9.15)and(92.10±10.26)ng/L(t=0.570,P>0.05),respectively.One day after the treatment,the VAS scores in the observation group and control group were(3.97±0.85)and(5.23±0.86)(t=5.742,P<0.05),respectively,and the IL-6 levels in the observation group and control group were(72.74±7.64)and(83.31±8.54)ng/L(t=5.056,P<0.05),respectively.One week af-ter the treatment,the VAS score was(3.23±0.77)in the observation group and(4.27±0.69)in the control group(t=5.454,P<0.05),and the serum IL-6 level was(64.06±6.02)ng/L in the observation group and(75.30±7.89)ng/L in the control group(t=6.204,P<0.05).One month after the treatment,the VAS score was(2.80±0.93)in the observation group and(3.57±0.57)in the control group(t=3.869,P<0.05),and the serum IL-6 level was(55.86±3.99)ng/L in the observation group and(64.05±5.74)ng/L in the control group(t=6.420,P<0.05).Three months after the treatment,the VAS score was(1.87±0.51)in the observation groups and(3.07±0.45)in the control group(t=9.693,P<0.05),and the serum IL-6 level was(48.10±6.10)ng/L in the observa-tion group and(55.48±3.39)ng/L in the control group(t=5.787,P<0.05).Conclusions The nerve block can effectively relieve postherpetic neuralgia.

Nerve blockPostherpetic neuralgiaInterleukin-6

罗睿韬、谭嵘

展开 >

湖南中医药大学医学院,湖南长沙 410208

中南大学湘雅二医院

神经阻滞 带状疱疹后神经痛 白介素-6

2024

河南预防医学杂志
河南省预防医学会

河南预防医学杂志

影响因子:0.409
ISSN:1006-8414
年,卷(期):2024.35(1)
  • 6